GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Exam Corner/Microvillus Inclusion Disease

Microvillus Inclusion Disease

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated September 1, 2025

Quick Answer

Microvillus Inclusion Disease (MVID) is a **rare, congenital intestinal disorder** that primarily affects infants and newborns. It is caused by genetic mutations that disrupt the normal function of the epithelial cells lining the small intestine, leading to **life-threatening diarrhea** and severe malabsorption.


Microvillus Inclusion Disease (MVID) is a **rare, congenital intestinal disorder** that primarily affects infants and newborns. It is caused by genetic mutations that disrupt the normal function of the epithelial cells lining the small intestine, leading to **life-threatening diarrhea** and severe malabsorption.

---

### **Key Features of MVID**

#### 1. **What Happens in MVID?**

  • **Microvilli**, which are tiny finger-like projections on the surface of intestinal cells (enterocytes), are either absent or abnormally trapped inside the cells in vesicles called "microvillus inclusions."
  • Microvilli are essential for nutrient absorption, and their dysfunction leads to severe diarrhea and inability to absorb nutrients.

#### 2. **Genetic Cause**

  • MVID is caused by mutations in genes involved in intracellular trafficking:
  • **MYO5B**: Most common mutation.
  • **STX3** and **STXBP2**: Less common mutations.
  • It is inherited in an **autosomal recessive** manner, meaning both parents must pass on a defective gene for the child to develop the disease.

#### 3. **Clinical Symptoms**

  • Symptoms usually appear within the **first days or weeks of life**.
  • **Severe diarrhea**: Watery and persistent.
  • **Dehydration**: Due to fluid loss.
  • **Failure to thrive**: Poor growth and malnutrition.
  • **Electrolyte imbalance**: Low levels of essential minerals due to diarrhea.
  • **Complications**:
  • Dependence on **parenteral nutrition** (IV feeding).
  • Risk of infections, liver damage, and sepsis from long-term IV feeding.

---

### **Diagnosis**

  • **Histopathology and Electron Microscopy**:
  • Flattened villi in the intestine (villus atrophy).
  • Microvillus inclusions visible inside enterocytes.
  • **Genetic Testing**: Identifies mutations in MYO5B, STX3, or STXBP2 genes.
  • **Immunohistochemistry**: May show abnormal protein expression in epithelial cells.

---

### **Treatment**

  • **No Cure**: MVID cannot be cured, but symptoms can be managed.
  • **Supportive Care**:
  • **Total Parenteral Nutrition (TPN)**: Provides nutrients intravenously to ensure growth and survival.
  • Infection control: Prevent complications like sepsis.
  • **Intestinal Transplantation**:
  • In severe cases, intestinal or combined liver–intestine transplantation may be considered for long-term survival.

---

### **Prognosis**

  • Without transplantation, prognosis is poor due to complications from TPN (e.g., infections, liver damage).
  • Advances in transplant surgery and supportive care have improved survival rates.

---

### **In Simple Terms**

Microvillus Inclusion Disease is a genetic disorder where babies are unable to absorb nutrients because their intestinal cells lack functioning microvilli. This leads to severe diarrhea, malnutrition, and dependence on IV feeding to survive. Treatment focuses on managing symptoms, and intestinal transplantation may offer a chance for better long-term outcomes.

Would you like additional information on **genetic inheritance patterns**, **recent research**, or **support groups** for families dealing with MVID?

Related Q&A

Dopamine Beyond Reward. JAMA| May 2026

This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The authors describe how distributed dopamine ensembles across...

Gut–Heart Axis: Gut | May 2026

Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now recognised as a key modulator of vascular...

Bleeding Risk with Apixaban vs. Rivaroxaban: NEJM March 2026

Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis. A total of 2,760...

ACG 2025

The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025 meeting, several impactful studies were showcased, providing...

Alcohol Use Disorder (AUD) with Alcohol-Related Liver Disease (ArLD) - Pharmacology

Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation starting from definitions, the need for pharmacological...

The role of copper dysregulation in Wilson disease

Copper dysregulation plays a central role in the pathogenesis of Wilson disease (WD). The disease arises from the body’s inability to regulate copper levels, leading to its accumulation and subsequent toxicity. Below is a detailed...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer